Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.11
ALRPRB's Cash to Debt is ranked lower than
55% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.91 vs. ALRPRB: 0.11 )
ALRPRB' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.11

Equity to Asset 0.30
ALRPRB's Equity to Asset is ranked higher than
51% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ALRPRB: 0.30 )
ALRPRB' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.77
Current: 0.3

-0.49
0.77
Interest Coverage 0.50
ALRPRB's Interest Coverage is ranked lower than
60% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. ALRPRB: 0.50 )
ALRPRB' s 10-Year Interest Coverage Range
Min: 0.04   Max: 3.6
Current: 0.5

0.04
3.6
F-Score: 6
Z-Score: 0.68
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.58
ALRPRB's Operating margin (%) is ranked higher than
71% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ALRPRB: 2.58 )
ALRPRB' s 10-Year Operating margin (%) Range
Min: -92.15   Max: 13.42
Current: 2.58

-92.15
13.42
Net-margin (%) -2.65
ALRPRB's Net-margin (%) is ranked higher than
66% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. ALRPRB: -2.65 )
ALRPRB' s 10-Year Net-margin (%) Range
Min: -149.74   Max: 6.61
Current: -2.65

-149.74
6.61
ROE (%) -3.82
ALRPRB's ROE (%) is ranked higher than
67% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. ALRPRB: -3.82 )
ALRPRB' s 10-Year ROE (%) Range
Min: -555.34   Max: 10.39
Current: -3.82

-555.34
10.39
ROA (%) -1.12
ALRPRB's ROA (%) is ranked higher than
68% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.28 vs. ALRPRB: -1.12 )
ALRPRB' s 10-Year ROA (%) Range
Min: -104.38   Max: 3.56
Current: -1.12

-104.38
3.56
ROC (Joel Greenblatt) (%) 7.50
ALRPRB's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. ALRPRB: 7.50 )
ALRPRB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -445.57   Max: 66.78
Current: 7.5

-445.57
66.78
Revenue Growth (%) 13.30
ALRPRB's Revenue Growth (%) is ranked higher than
89% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. ALRPRB: 13.30 )
ALRPRB' s 10-Year Revenue Growth (%) Range
Min: -8.6   Max: 73
Current: 13.3

-8.6
73
EPS Growth (%) -55.10
ALRPRB's EPS Growth (%) is ranked higher than
50% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ALRPRB: -55.10 )
ALRPRB' s 10-Year EPS Growth (%) Range
Min: -55.1   Max: 75.3
Current: -55.1

-55.1
75.3
» ALRPRB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ALRPRB Guru Trades in Q3 2013

Howard Marks 207,800 sh (+8.91%)
Pioneer Investments 127,839 sh (unchged)
Private Capital 5,342 sh (-0.37%)
» More
Q4 2013

ALRPRB Guru Trades in Q4 2013

Howard Marks 212,800 sh (+2.41%)
Pioneer Investments 127,839 sh (unchged)
Private Capital 5,342 sh (unchged)
» More
Q1 2014

ALRPRB Guru Trades in Q1 2014

Pioneer Investments 127,839 sh (unchged)
Private Capital 5,342 sh (unchged)
Howard Marks 212,800 sh (unchged)
» More
Q2 2014

ALRPRB Guru Trades in Q2 2014

Howard Marks 212,800 sh (unchged)
Pioneer Investments 127,839 sh (unchged)
Private Capital 5,337 sh (-0.09%)
» More
» Details

Insider Trades

Latest Guru Trades with ALRPRB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB15.423.64

Ratios

vs
industry
vs
history
P/B 2.27
ALRPRB's P/B is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.12 vs. ALRPRB: 2.27 )
ALRPRB' s 10-Year P/B Range
Min: 0.42   Max: 2.75
Current: 2.27

0.42
2.75
P/S 1.10
ALRPRB's P/S is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. ALRPRB: 1.10 )
ALRPRB' s 10-Year P/S Range
Min: 0.52   Max: 4.12
Current: 1.1

0.52
4.12
PFCF 19.32
ALRPRB's PFCF is ranked higher than
92% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALRPRB: 19.32 )
ALRPRB' s 10-Year PFCF Range
Min: 7.62   Max: 135.97
Current: 19.32

7.62
135.97
EV-to-EBIT 95.20
ALRPRB's EV-to-EBIT is ranked higher than
71% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. ALRPRB: 95.20 )
ALRPRB' s 10-Year EV-to-EBIT Range
Min: 34.2   Max: 2833.4
Current: 95.2

34.2
2833.4
Current Ratio 2.25
ALRPRB's Current Ratio is ranked higher than
67% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ALRPRB: 2.25 )
ALRPRB' s 10-Year Current Ratio Range
Min: 0.7   Max: 3.42
Current: 2.25

0.7
3.42
Quick Ratio 1.70
ALRPRB's Quick Ratio is ranked higher than
61% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. ALRPRB: 1.70 )
ALRPRB' s 10-Year Quick Ratio Range
Min: 0.46   Max: 2.89
Current: 1.7

0.46
2.89

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.64
ALRPRB's Dividend Yield is ranked lower than
215% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.22 vs. ALRPRB: 3.64 )
ALRPRB' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 3.64

Yield on cost (5-Year) 3.64
ALRPRB's Yield on cost (5-Year) is ranked lower than
85% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.52 vs. ALRPRB: 3.64 )
ALRPRB' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 3.64

Share Buyback Rate 1.20
ALRPRB's Share Buyback Rate is ranked higher than
94% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. ALRPRB: 1.20 )
ALRPRB' s 10-Year Share Buyback Rate Range
Min: 19.3   Max: -54.7
Current: 1.2

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 1.10
ALRPRB's Earnings Yield (Greenblatt) is ranked higher than
50% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. ALRPRB: 1.10 )
ALRPRB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 2.9
Current: 1.1

0.3
2.9
Forward Rate of Return (Yacktman) 3.52
ALRPRB's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. ALRPRB: 3.52 )
ALRPRB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2   Max: 9.1
Current: 3.52

-2
9.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:IM5.Germany
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take charge of improving their health and quality of life at home by developing new capabilities in near-patient diagnosis, monitoring and health management. The Company's global products and services, as well as its new product development efforts, focuses on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. The Company's main reportable operating segments are professional diagnostics, health management and consumer diagnostics. Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals and doctors' offices and, increasingly, testing and monitoring done at home at the direction of the medical professional, or through patient self-testing. Professional diagnostic products provide for qualitative or quantitative analysis of a patient's body fluids or tissue for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The Company's health management business strives to empower participants of its programs and physicians so they could work together towards better health. It also provides services supporting home INR testing. Its health management business is principally conducted in the United States. The Company's other current consumer diagnostic products consist of its market-leading First Check brand of over-the-counter drugs of abuse tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for alcohol abuse, cholesterol monitoring and colon cancer screening. The Company's manufacturing facilities are located in San Diego, California; Scarborough, Maine; Dundee, Scotland; Oslo, Norway; Hangzhou and Shanghai, China; Matsudo, Japan; and Yongin, South Korea. It also manufactures products at a number of other facilities in the United States, Australia, Germany, India, Israel, South Africa, Spain and the United Kingdom. Its competitors in the United States and abroad are numerous and include, among others, diagnostic testing and medical products companies, universities and other research institutions, health management service providers, healthcare providers and health insurers. The main competitors for its professional rapid diagnostic products are Becton Dickinson, Quidel and Meridian Bioscience.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK